Hemostemix (FRA:2VF0) Cyclically Adjusted PB Ratio: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Hemostemix Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Hemostemix  (FRA:2VF0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Hemostemix Cyclically Adjusted PB Ratio Related Terms


Hemostemix Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Hemostemix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemostemix Cyclically Adjusted PB Ratio Chart

Hemostemix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.23 0.84 0.00 0.00

Hemostemix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:2VF0 vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Hemostemix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemostemix Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemostemix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Hemostemix's Cyclically Adjusted PB Ratio falls into.



Hemostemix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Hemostemix's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Hemostemix's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.017/132.2623*132.2623
=-0.017

Current CPI (Mar. 2026) = 132.2623.

Hemostemix Quarterly Data

Book Value per Share CPI Adj_Book
201606 -0.218 102.002 -0.283
201609 -0.409 101.765 -0.532
201612 -0.677 101.449 -0.883
201703 -0.494 102.634 -0.637
201706 -0.559 103.029 -0.718
201709 0.248 103.345 0.317
201712 0.216 103.345 0.276
201803 0.175 105.004 0.220
201806 0.136 105.557 0.170
201809 0.085 105.636 0.106
201812 0.021 105.399 0.026
201903 -0.029 106.979 -0.036
201906 -0.077 107.690 -0.095
201909 -0.136 107.611 -0.167
201912 -0.184 107.769 -0.226
202003 -0.050 107.927 -0.061
202006 -0.047 108.401 -0.057
202009 -0.068 108.164 -0.083
202012 -0.013 108.559 -0.016
202103 -0.019 110.298 -0.023
202106 -0.019 111.720 -0.022
202109 -0.025 112.905 -0.029
202112 -0.062 113.774 -0.072
202203 -0.058 117.646 -0.065
202206 -0.048 120.806 -0.053
202209 -0.039 120.648 -0.043
202212 -0.062 120.964 -0.068
202303 -0.059 122.702 -0.064
202306 -0.057 124.203 -0.061
202309 -0.054 125.230 -0.057
202312 -0.058 125.072 -0.061
202403 0.000 126.258 0.000
202406 -0.065 127.522 -0.067
202409 -0.066 127.285 -0.069
202412 -0.034 127.364 -0.035
202503 -0.033 129.181 -0.034
202506 -0.031 129.892 -0.032
202509 -0.012 130.287 -0.012
202512 -0.016 130.366 -0.016
202603 -0.017 132.262 -0.017

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hemostemix Business Description

Other Exchanges HMTXF:USAHEM:Canada
Address 707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Hemostemix Inc is a clinical-stage biotechnology company whose principal business is to develop, manufacture, and commercialize blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments. Its product ACP-01 is derived from a patient's own blood and evaluated in clinical research for ischemic conditions, including Cardiovascular Ischemia, Peripheral Arterial Disease (PAD), Chronic Limb Threatening Ischemia (CLTI), and Vascular Dementia.